GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Gross Profit

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Gross Profit : $0.89 Mil (TTM As of Aug. 2023)


View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Gross Profit?

IntelliPharmaCeutics International's gross profit for the three months ended in Aug. 2023 was $0.05 Mil. IntelliPharmaCeutics International's gross profit for the trailing twelve months (TTM) ended in Aug. 2023 was $0.89 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. IntelliPharmaCeutics International's gross profit for the three months ended in Aug. 2023 was $0.05 Mil. IntelliPharmaCeutics International's Revenue for the three months ended in Aug. 2023 was $0.07 Mil. Therefore, IntelliPharmaCeutics International's Gross Margin % for the quarter that ended in Aug. 2023 was 73.91%.

IntelliPharmaCeutics International had a gross margin of 73.91% for the quarter that ended in Aug. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of IntelliPharmaCeutics International was 99.02%. The lowest was -232.42%. And the median was 87.21%.


IntelliPharmaCeutics International Gross Profit Historical Data

The historical data trend for IntelliPharmaCeutics International's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Gross Profit Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.59 3.45 1.40 - 0.07

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.03 0.33 0.48 0.05

Competitive Comparison of IntelliPharmaCeutics International's Gross Profit

For the Biotechnology subindustry, IntelliPharmaCeutics International's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Gross Profit distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Gross Profit falls into.



IntelliPharmaCeutics International Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

IntelliPharmaCeutics International's Gross Profit for the fiscal year that ended in Nov. 2022 is calculated as

Gross Profit (A: Nov. 2022 )=Revenue - Cost of Goods Sold
=0.066 - 0
=0.07

IntelliPharmaCeutics International's Gross Profit for the quarter that ended in Aug. 2023 is calculated as

Gross Profit (Q: Aug. 2023 )=Revenue - Cost of Goods Sold
=0.069 - 0.018
=0.05

Gross Profit for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.89 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

IntelliPharmaCeutics International's Gross Margin % for the quarter that ended in Aug. 2023 is calculated as

Gross Margin % (Q: Aug. 2023 )=Gross Profit (Q: Aug. 2023 ) / Revenue (Q: Aug. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.05 / 0.069
=73.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


IntelliPharmaCeutics International  (OTCPK:IPCIF) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

IntelliPharmaCeutics International had a gross margin of 73.91% for the quarter that ended in Aug. 2023 => Durable competitive advantage


IntelliPharmaCeutics International Gross Profit Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Headlines